“The pivotal, GLP-compliant toxicology studies were conducted in cynomolgus monkey, the only biologically relevant species”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Why that species
High affinity for monkey and human CGRP-R; no affinity for rodent CGRP-R or related family members
“Erenumab has high affinity for the monkey and human CGRP-R, but not for rodent CGRP-R or closely related CGRP-R family members.”
✓ VerifiedFDA pharmacology/toxicology review, p. 14Source ↗
Surrogate molecule
No surrogate; the clinical antibody was tested in monkeys (no pharmacological activity in other species)
“General toxicology studies were conducted exclusively in monkeys, due to a lack of pharmacological activity in other species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗
Species: general tox
Cynomolgus monkey only (no pharmacological activity in other species)
“General toxicology studies were conducted exclusively in monkeys, due to a lack of pharmacological activity in other species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗
Species: DART
Cynomolgus monkey (single enhanced PPND study); no separate fertility study
“The reproductive and developmental toxicology package consisted of a single enhanced PPND study in monkey, with dosing at 0 and 50 mg/kg”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗
Species: carcinogenicity
Not conducted (waived; erenumab inactive in rodents)
“Carcinogenicity studies were waived, based on the lack of erenumab activity in rodents, histopathological data from the submitted toxicology studies showing no carcinogenic risk factors (i.e. hyperplasia or neoplasia)”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗
Surrogate used in
No surrogate used; clinical antibody tested in monkeys only
“General toxicology studies were conducted exclusively in monkeys, due to a lack of pharmacological activity in other species.”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗